((自动化翻译由路透提供,请见免责声明 ))
路透10月31日 - 美国食品和药物管理局的独立顾问周四投票反对推荐Lexicon Pharmaceuticals公司的 作为胰岛素疗法的附加疗法,用于控制1型糖尿病和慢性肾病成人患者的血糖水平。
专家组以13票对3票反对推荐这种化学名称为索他利氟嗪(sotagliflozin)的药物。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.